First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 ...

Eli Lilly said its targeted cancer therapy Retevmo significantly reduced the risk of disease recurrence or death in patients with e ...

An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday.

An experimental drug developed by China-based Akeso helped patients with advanced squamous non-small cell lung cancer live 15% longer than BeOne Medicines' immunotherapy Tevimbra, and cut the risk ...

Experts have described the findings as a ‘promising step forward‘ for patients with advanced squamous non-small cell lung cancer ...

It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | ...

First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 ...

Matthew Herper covers medical innovation — both its promise and its perils. CHICAGO — Ivonescimab, a drug that combines the activity of two of the best-selling cancer medicines, reduced the risk of ...

Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an ...

A lung cancer drug developed by Akeso Inc. extended patients’ lives by about four months in a late-stage trial in China, ...

In the race to forge the next Keytruda from PD-(L)1xVEGF bispecific antibodies, Pfizer and the BioNTech-Bristol Myers Squibb alliance are split on how to position overall survival—the gold-standard ...

Eli Lilly looks set to extend the reach of its RET inhibitor Retevmo in RET-mutated tumours, as the LIBRETTO-432 trial shows its value in an adjuvant lung cancer setting. The LIBRETTO-432 trial showed ...